Background: Interleukin 8 (IL-8) has recently been under focused investigation because of its possible participation in the evolution of Adamantiades-Behçet’s disease. Objective: The reliability of IL-8 as a serological marker for the activity of the disease was investigated in a prospective consecutive trial of 34 cases. Methods: The activity of the disease was clinically evaluated by the number of actively involved organ systems registered on the day of blood sampling and by the presence of oral aphthous ulcers. Serum IL-8 levels were compared to C-reactive protein (CRP) values and the erythrocyte sedimentation rate. Results: An association of IL-8 levels with the activity of the disease was detected when compared with both the number of active clinical signs (p = 0.024) and the presence of oral aphthous ulcers (p = 0.002). In contrast, no association of CRP and sedimentation rate with the activity of the disease could be detected. A weak correlation of IL-8 levels with sedimentation rate values at 2 h was found (R = 0.37, p = 0.032). Conclusion: Our results confirm previous data concerning the significance of IL-8 and, in addition, they provide first evidence for the reliability of IL-8 as a serological marker for assessment of the activity of Adamantiades-Behçet’s disease in the follow-up of clinical and therapeutic studies.

Keywords:
Behçet’s disease, Interleukin 8, Erythrocyte sedimentation rate, C-reactive protein
1.
Rizzi B, Bruno S, Dammacco R: Behçet’s disease: An immune-mediated vasculitis involving vessels of all sizes. Int J Clin Lab Res 1997;27:225–232.
2.
International Study Group for Behçet’s disease: Criteria for diagnosis of Behçet’s disease. Lancet 1990;335:1078–1080.
3.
Davatchi F, Shahram F, Akbarian M, Gharibdoost F, Chams C, Champs H, Mansoori P, Nadji A: Classification tree for the diagnosis of Behçet’s disease; in Wechsler B, Godeau P (eds): Behçet’s Disease. International Congress Series 1037. Amsterdam, Excerpta Medica, Amsterdam, 1993, pp 245–248.
4.
Itoh R, Takenaka T, Okitsu-Negishi S, Matsushima K, Mizogouchi M: Interleukin-8 in Behçet’s disease. J Dermatol 1994;21:397–404.
5.
al-Dalaan A, al-Sedairy S, al-Balaa S, al-Janadi M, Elramahi K, Bahabri S, Siddiqui S: Enhanced interleukin 8 secretion in circulation of patients with Behçet’s disease. J Rheumatol 1995;22:904–907.
6.
Ozoran K, Aydintug O, Tokgöz G, Düzgün N, Tutkak H, Gürler A: Serum levels of interleukin-8 in patients with Behçet’s disease. Ann Rheum Dis 1995;54:610.
7.
Sahin S, Akoglu T, Direskeneli H, Sen LS, Lawrence R: Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet’s disease. Ann Rheum Dis 1996;55:128–133.
8.
Wang LM, Kitteringham N, Mineshita S, Wang JZ, Nomura Y, Koike Y, Miyashita E: The demonstration of serum interleukin-8 and superoxide dismutase in Adamantiades-Behçet’s disease. Arch Dermatol Res 1997;289:444–447.
9.
Zouboulis ChC, Treudler R, Katsantonis J, Ketteler R, Kaklamani E, Hornemann S, Kaklamanis Ph, Tebbe B, Orfanos CE: Adamantiades-Behçet’s disease: Interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. J Eur Acad Dermatol Venereol 1999;12(suppl 2):S181–S182.
10.
International Council for Standardization in Haematology: ICSH recommendations for measurement of erythrocyte sedimentation rate. J Clin Pathol 1993;46:198–203.
11.
Dixon JS, Yurdakul S, Surrall KE, Yazici H, Chamberlain MA: A study of serum biochemistry in Behçet’s disease. Br J Rheumatol 1984;23:283–287.
12.
Müftüoglou AÜ, Yazici H, Yurdakul S, Tüzün Y, Pazarli H, Güngen G, Deniz S: Behçet’s disease: Relation of serum C-reactive protein and erythrocyte sedimentation rate to disease activity. Int J Dermatol 1986;25:235–239.
13.
Aydintug AO, Tokgöz G, Ozoran K, Düzgün N, Gürler A, Tutkak H: Elevated levels of soluble intercellular adhesion molecule-1 correlate with disease activity in Behçet’s disease. Rheumatol Int 1995;15:75–78.
14.
Turan B, Gallati H, Erdi H, Gürler A, Michel BA, Villinger PM: Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet’s disease: Soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997;24:128–132.
15.
Rot A: Endothelial cell binding of NAP1/IL-8: Role in neutrophil migration. Immunol Today 1992;13:291–294.
16.
Matsushima K, Baldwin E, Mukaida N: Interleukin-8 and MCAF: Novel leucocyte recruitment and activating cytokines. Chem Immunol 1992;51:236–265.
17.
Kienbaum S, Zouboulis ChC, Waibel M, Orfanos CE: Chemotactic neutrophilic vasculitis: A new histopathological pattern of vasculitis found in mucocutaneous lesions of patients with Adamantiades-Behçet’s disease; in Wechsler B, Godeau P (eds): Behçet’s Disease. International Congress Series 1037. Amsterdam, Excerpta Medica, 1993, pp 337–341.
18.
Treudler R, Zouboulis ChC, Büttner P, Detmar M, Orfanos CE: Enhanced interaction of patients’ lymphocytes with human dermal microvascular endothelial cell cultures in active Adamantiades-Behçet’s disease. Arch Dermatol 1996;132:1323–1329.
19.
Lee KH, Chung HS, Bang D, Lee S: Behçet’s disease sera containing antiendothelial cell antibodies promote adhesion of T lymphocytes to cultured human dermal microvascular endothelial cells. Yonsei Med J 1999;40:152–158.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.